ACRS logo

Aclaris Therapeutics (ACRS) EBITDA

Annual EBITDA

-$51.72 M
+$63.73 M+55.20%

December 1, 2024

Summary

Performance

1-Year Change

+55.2%

3-Year Change

+19.77%

5-Year Change

+39.45%

15-Year Change

+2.34%

ACRS EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

31.06%
ACRS annual EBITDA is higher than 31.06% of companies in Healthcare sector

High & Low

All-time High

-$5.25 M

3-Year Low

-$115.45 M

Earnings dates

Last Annual Earnings Report Date

Dec 1, 2024
ACRS previous annual earnings announcement was published on Dec 1, 2024

Next Annual Earnings Report Date

N/A
ACRS next annual earnings announcement has not yet been scheduled

OtherACRSprofitabilitymetrics:

Annual Revenue

$18.72 M
ACRS annual revenue is $18.72 million

Annual Net Income

-$132.06 M
ACRS annual net profit is -$132.06 million

Annual EBIT

-$52.53 M
ACRS annual earnings before interest & taxes is -$52.53 million

Annual EPS

-$1.71
ACRS annual earnings per share is -$1.71

Quarterly EBITDA

-$13.93 M
-$4.43 M-46.72%

December 1, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+40.71%

3-Year Change

+32.05%

5-Year Change

-5.8%

ACRS Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

29.38%
ACRS quarterly EBITDA is higher than 29.38% of companies in Healthcare sector

High & Low

All-time High

-$2.57 M

3-Year Low

-$32.08 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 1, 2024
ACRS previous earnings announcement was published on Dec 1, 2024

Next Quarterly Earnings Report Date

May 7, 2025
ACRS next earnings announcement is scheduled for May 7, 2025

OtherACRSprofitabilitymetrics:

Quarterly Revenue

$9.21 M
ACRS quarterly revenue is $9.21 million

Quarterly Net Income

-$96.55 M
ACRS quarterly net profit is -$96.55 million

Quarterly EBIT

-$14.07 M
ACRS quarterly earnings before interest & taxes is -$14.07 million

Quarterly EPS

-$1.21
ACRS quarterly earnings per share is -$1.21

TTM EBITDA

-$51.72 M
+$9.56 M+15.60%

December 1, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+55.2%

3-Year Change

+19.77%

5-Year Change

+29.88%

ACRS TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

31.51%
ACRS TTM EBITDA is higher than 31.51% of companies in Healthcare sector

High & Low

All-time High

-$2.66 M

3-Year Low

-$115.45 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 1, 2024
ACRS previous earnings announcement was published on Dec 1, 2024

Next Quarterly Earnings Report Date

May 7, 2025
ACRS next earnings announcement is scheduled for May 7, 2025

OtherACRSprofitabilitymetrics:

TTM Revenue

$18.72 M
ACRS TTM revenue is $18.72 million

TTM Net Income

-$132.06 M
ACRS TTM net profit is -$132.06 million

TTM EBIT

-$52.53 M
ACRS TTM earnings before interest & taxes is -$52.53 million

TTM EPS

-$1.71
ACRS TTM earnings per share is -$1.71

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$51.72 M
ACRS annual EBITDA is -$51.72 million

Annual Net Income

-$132.06 M
ACRS annual net profit is -$132.06 million

Annual Interest Expense

-
ACRS annual interest expense value is unknown

Annual Income Tax

$0.00
ACRS annual income tax is $0.00

Annual D&A

$807.00 K
ACRS annual depreciation & amortization is $807.00 thousand

ACRS EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+55.2%+40.7%+55.2%
3 y3 years+19.8%+32.0%+19.8%
5 y5 years+39.5%-5.8%+29.9%

ACRS EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+55.2%-46.7%+56.6%at high+55.2%
5 y5-year-9.6%+55.2%-50.6%+56.6%-14.0%+55.2%
alltimeall time-885.9%+55.2%-441.1%+56.6%-1845.0%+55.2%

Aclaris Therapeutics EBITDA History

DateAnnualQuarterlyTTM
Dec 2024
-$51.72 M(-55.2%)
-$13.93 M(+46.7%)
-$51.72 M(-15.6%)
Sep 2024
-
-$9.49 M(-23.5%)
-$61.28 M(-24.5%)
Jun 2024
-
-$12.41 M(-21.9%)
-$81.16 M(-19.5%)
Mar 2024
-
-$15.89 M(-32.4%)
-$100.82 M(-12.7%)
Dec 2023
-$115.45 M(+36.9%)
-$23.49 M(-20.0%)
-$115.45 M(+1.5%)
Sep 2023
-
-$29.36 M(-8.5%)
-$113.75 M(+10.6%)
Jun 2023
-
-$32.08 M(+5.1%)
-$102.87 M(+8.3%)
Mar 2023
-
-$30.52 M(+40.1%)
-$94.98 M(+12.6%)
Dec 2022
-$84.36 M(+30.9%)
-$21.79 M(+17.9%)
-$84.36 M(+1.6%)
Sep 2022
-
-$18.48 M(-23.6%)
-$83.06 M(-0.9%)
Jun 2022
-
-$24.19 M(+21.6%)
-$83.79 M(+15.5%)
Mar 2022
-
-$19.90 M(-2.9%)
-$72.56 M(+12.6%)
Dec 2021
-$64.46 M(+36.6%)
-$20.50 M(+6.7%)
-$64.46 M(+12.1%)
Sep 2021
-
-$19.20 M(+48.2%)
-$57.52 M(+20.9%)
Jun 2021
-
-$12.96 M(+9.8%)
-$47.57 M(+4.8%)
Mar 2021
-
-$11.80 M(-13.0%)
-$45.38 M(-2.9%)
Dec 2020
-$47.20 M(-44.7%)
-$13.56 M(+46.6%)
-$46.75 M(-5.9%)
Sep 2020
-
-$9.25 M(-14.2%)
-$49.69 M(-19.4%)
Jun 2020
-
-$10.78 M(-18.1%)
-$61.67 M(-16.4%)
Mar 2020
-
-$13.16 M(-20.2%)
-$73.76 M(-13.7%)
Dec 2019
-$85.41 M
-$16.50 M(-22.3%)
-$85.42 M(-8.6%)
DateAnnualQuarterlyTTM
Sep 2019
-
-$21.23 M(-7.1%)
-$93.51 M(+0.3%)
Jun 2019
-
-$22.86 M(-7.9%)
-$93.23 M(-7.3%)
Mar 2019
-
-$24.82 M(+1.0%)
-$100.53 M(-5.5%)
Dec 2018
-$82.90 M(+56.5%)
-$24.59 M(+17.3%)
-$106.43 M(+19.5%)
Sep 2018
-
-$20.96 M(-30.5%)
-$89.05 M(+2.7%)
Jun 2018
-
-$30.16 M(-1.8%)
-$86.73 M(+22.5%)
Mar 2018
-
-$30.73 M(+326.8%)
-$70.81 M(+33.7%)
Dec 2017
-$52.96 M(+10.0%)
-$7.20 M(-61.4%)
-$52.96 M(-7.2%)
Sep 2017
-
-$18.64 M(+30.9%)
-$57.05 M(+16.0%)
Jun 2017
-
-$14.24 M(+10.6%)
-$49.19 M(+2.7%)
Mar 2017
-
-$12.88 M(+14.1%)
-$47.91 M(-0.5%)
Dec 2016
-$48.15 M(+134.0%)
-$11.29 M(+4.7%)
-$48.15 M(+15.7%)
Sep 2016
-
-$10.78 M(-16.8%)
-$41.63 M(+0.4%)
Jun 2016
-
-$12.96 M(-1.2%)
-$41.46 M(+33.4%)
Mar 2016
-
-$13.12 M(+175.1%)
-$31.07 M(+51.0%)
Dec 2015
-$20.58 M(+141.5%)
-$4.77 M(-55.0%)
-$20.58 M(+11.8%)
Sep 2015
-
-$10.61 M(+312.1%)
-$18.41 M(+76.0%)
Jun 2015
-
-$2.57 M(-2.0%)
-$10.46 M(+32.6%)
Mar 2015
-
-$2.63 M(+1.0%)
-$7.88 M(+49.9%)
Dec 2014
-$8.52 M(+62.4%)
-$2.60 M(-2.3%)
-$5.26 M(+97.7%)
Sep 2014
-
-$2.66 M
-$2.66 M
Dec 2013
-$5.25 M
-
-

FAQ

  • What is Aclaris Therapeutics annual EBITDA?
  • What is the all time high annual EBITDA for Aclaris Therapeutics?
  • What is Aclaris Therapeutics annual EBITDA year-on-year change?
  • What is Aclaris Therapeutics quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Aclaris Therapeutics?
  • What is Aclaris Therapeutics quarterly EBITDA year-on-year change?
  • What is Aclaris Therapeutics TTM EBITDA?
  • What is the all time high TTM EBITDA for Aclaris Therapeutics?
  • What is Aclaris Therapeutics TTM EBITDA year-on-year change?

What is Aclaris Therapeutics annual EBITDA?

The current annual EBITDA of ACRS is -$51.72 M

What is the all time high annual EBITDA for Aclaris Therapeutics?

Aclaris Therapeutics all-time high annual EBITDA is -$5.25 M

What is Aclaris Therapeutics annual EBITDA year-on-year change?

Over the past year, ACRS annual EBITDA has changed by +$63.73 M (+55.20%)

What is Aclaris Therapeutics quarterly EBITDA?

The current quarterly EBITDA of ACRS is -$13.93 M

What is the all time high quarterly EBITDA for Aclaris Therapeutics?

Aclaris Therapeutics all-time high quarterly EBITDA is -$2.57 M

What is Aclaris Therapeutics quarterly EBITDA year-on-year change?

Over the past year, ACRS quarterly EBITDA has changed by +$9.56 M (+40.71%)

What is Aclaris Therapeutics TTM EBITDA?

The current TTM EBITDA of ACRS is -$51.72 M

What is the all time high TTM EBITDA for Aclaris Therapeutics?

Aclaris Therapeutics all-time high TTM EBITDA is -$2.66 M

What is Aclaris Therapeutics TTM EBITDA year-on-year change?

Over the past year, ACRS TTM EBITDA has changed by +$63.73 M (+55.20%)